Descrição
Glioblastoma (GBM) is a highly malignant brain tumor with a high risk of recurrence and mortality. Current GBM therapy has limited effectiveness due to the invasive and heterogeneous nature of the tumor. (1) Synthetic chromene-based molecules have proven their potential for cancer treatment, acting on several molecular targets involved in cancer progression. (2) Here, the chicken chorioallantoic membrane (CAM) assay was employed as a well-established in vivo model to investigate the antitumoral and antiangiogenic activity of cell membrane-coated poly(lactide-co-glycolide) (PLGA) nanoparticles (NPs) containing novel chromene-based molecules (mNP@CBM) against a 3D tumor formed by the U87 cell line implanted into the CAM. Our analysis revealed that tumors treated with the negative control (DMEM 10% FBS) exhibited an approximately 23% increase in size, whereas those treated with mNP@CBM showed a significant 19% regression in tumor growth. Furthermore, the substantial reduction in tumor size observed with mNP@CBM aligns with our previous findings regarding cell viability, demonstrating the therapeutic benefits of the cell-membrane coating process. To quantify blood vessel density, CAMs with tumors were excised and examined. Treatment with NPs resulted in a weakened vascular network, indicating a potential antiangiogenic effect associated with their antitumoral activity. These findings highlight the potential of the proposed delivery system in combating glioma cell lines. Therefore, developed nanoparticles may open a new therapeutic opportunity for GBM treatment.
Acknowledgments: This study was supported by CAPES
Referências
1 LEE, S.Y. Temozolomide resistance in glioblastoma multiforme. Genes and Diseases, v. 3, n. 3, p. 198-210, Sept. 2016.
2 COSTA, M. et al. Biological importance of structurally diversified chromenes. European Journal of Medicinal Chemistry, v. 123, p. 487-507, July 2016.
| Certifico que os nomes citados como autor e coautor estão cientes de suas nomeações. | Sim |
|---|---|
| Palavras-chave | Glioblastoma. Biomimetic nanoparticles. CAM assay. |
| Orientador e coorientador | Valtencir Zucolotto. Natalia Noronha Ferreira |
| Subárea 1 | Física Aplicada à Biologia e à Medicina |
| Subárea 2 (opcional) | Biotecnologia |
| Agência de Fomento | CAPES |
| Número de Processo | 88887.821847/2023-00 |
| Modalidade | DOUTORADO |
| Concessão de Direitos Autorais | Sim |
